TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Systemic release of sCD14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in BAL levels of biomarkers for inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: local progression-free survival after tumour resection
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to retreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local control rate in clinical T2 tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PMA index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD (periodontal disease) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: malapposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinic BP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HR increase with felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma NE levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Attendance at training sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Implementation of TIME components
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maintenance of TIME usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cholera with severe dehydration (CSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of correct calculations within +/-5% of the correct value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in QALYs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean marginal bone level (MBL) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 bioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C reactive protein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nervous functional deficit score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Atherothrombotic stroke event rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lacunar stroke event rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnoea-hypopnoea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of oral morphine therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of neonatal hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Vitamin K deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: literacy and phonological measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vocabulary and grammatical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of epileptiform discharges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Successful closure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of air-bone gap (ABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TL counts from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LV end‐diastolic volume (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: processing efficiency of brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of inflammatory cells in nasal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TMD symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of post-dural puncture headaches (PDPHs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laparoscopic entry time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mesenteric injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of use of CBT skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skill quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of the IV condition
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Etoricoxib area under the plasma concentration-time curve (AUC(0-00))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decline in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Less sexual intercourse in the previous 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: More consistent condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less unprotected intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A3H3max shortening after ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achieving HbA1c < 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in defect score 1 month after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asynergic score improvement at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIMI grade reflow after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Articular angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Night-time SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of BP in OBPM - SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended BP control in ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: International normalized ratio (INR) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Noncompliance rate
Endpoint domain: Adverse events/effects
Primary endpoint: Contamination rate
Endpoint domain: Adverse events/effects
Primary endpoint: intention to return to smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in MSFC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response following 12 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rate for H pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative DASH scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIQ scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lesion volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to resolution of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maternal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum total and ionized calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of intrapartum fever
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative serum hs‐cTnT concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate Variability (HRV) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Energy Expenditure (EE) AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum active GLP-1 AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hunger sensations
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: general functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma GLP-1 level accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DPP-IV inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PPBC improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrence of UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain after immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability after immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OMA response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dominant tumor infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peak esophageal eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in work productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean sick leave attributable to reflux symptoms
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: postprandial triglyceride incremental area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total triglyceride area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's total cycling skill score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean level of PCA formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean drain removal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insertion related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Combined incidence of MACE during follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Ejection fraction at 5-7 days after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of responders to vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunoglobulin G antibody geometric mean concentration/titer ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean perceived exertion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen declines > or = 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthostatic tolerance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell surface expression of CD23, CD40 and HLA-DR on B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentration of IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to the program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: actionable bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: overall clinical events (MI + bleeding)
Endpoint domain: Adverse events/effects
Primary endpoint: End Diastolic Velocity (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N-acetylaspartate/creatine (NAA/Cr) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recovery time of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-body protein breakdown rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte mitogenic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of small bowel length measurement during laparoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normalization of HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of gastroesophageal reflux (GER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of tracheal acid aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abstinence from smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healing of venous ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical treatment success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic treatment success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral adipose tissue (VAT) accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial carbohydrate utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful follow up until seven months of age
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to recovery (movement and intestinal function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean IRLS score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRLS responder rate (≥50% score reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-month incidence of confirmed augmentation
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma imatinib concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N1 latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: N2 amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P2 latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effective rate of focal absorption examined by X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative conversion rate of bacteria in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum PRO‐C5 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CICP concentrations in wound fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expectation of maximum aggregate benefit (EMAB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: evolution of serum VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: additional infant surviving without severe NDI
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute symptomatic cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of symptomatic urinary tract infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient preference for TSPCD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean colony-forming units (CFU)/g of total microorganisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean maximum plasma concentration of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean AUC(0-12) values for morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of Oramorph SR 30 mg and MST-30 Mundipharma Retardtabletten
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of masseter muscle rehypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum gastrin integrated value (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: frequency of electrical waves (tachygastria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: power ratio (postprandial/fasting total power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Size of skin pores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Volume of reserved sebum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Initial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting energy expenditure (REE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined treatment and opportunity costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: plasma copeptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one repetition maximum bench press and squat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved targeted range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking distance (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSQ self-care score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: body mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior Capsule Opacification (PCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary aspiration episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Total bilirubin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biocompatibility of glass ionomer cement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-weighted hourly consumption of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to first PCEA self-bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of metaphase II oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: safety of single-wall puncture technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall adequacy of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for supplemental narcotics or droperidol
Endpoint domain: Adverse events/effects
Primary endpoint: presence of retching interfering with the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: premature delivery
Endpoint domain: Mortality/survival